Article (Scientific journals)
Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Stockis, Armel; Watanabe, Shikiko; Scheen, André
2015In Journal of Clinical Pharmacology
Peer Reviewed verified by ORBi
 

Files


Full Text
2015 Stockis_BRV midazolam JCP2015_aheadofprint_full-paper.pdf
Publisher postprint (189.3 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
CYP3A; brivaracetam; interaction; midazolam; pharmacokinetics
Abstract :
[en] Brivaracetam is a synaptic vesicle protein 2A ligand in phase III development for epilepsy. A phase I, open-label, randomized study was conducted in 42 healthy male participants to assess the effect of brivaracetam on CYP3A activity using midazolam as a probe. Participants were randomized to oral brivaracetam 5, 50, or 150 mg/day from Day 8 to Day 14. A single oral dose (7.5 mg) of midazolam was administered on Days 1, 13, and 20, and full pharmacokinetic profiles were obtained. For all brivaracetam doses, the areas under the plasma concentration-time curves from 0 to infinity (AUCinf ) for midazolam and 1'-hydroxymidazolam were similar on Days 13 and 20 compared with Day 1. Following brivaracetam 150 mg/day, the Day 13/Day 1 AUCinf ratio (90% confidence interval) was 1.09 (0.97, 1.21) and 1.04 (0.93, 1.17) for midazolam and 1'-hydroxymidazolam, respectively. For the Day 20/Day 1 comparison, the corresponding AUCinf ratios were 1.10 (0.98, 1.23) and 1.07 (0.97, 1.18). Maximum midazolam plasma concentration was increased on both Day 13 and Day 20 vs. Day 1 but the relevance of this finding was unclear. This study indicates that brivaracetam up to 150 mg/day has no significant inducing or inhibiting effect on CYP3A activity.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Stockis, Armel
Watanabe, Shikiko
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
English
Title :
Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Publication date :
2015
Journal title :
Journal of Clinical Pharmacology
ISSN :
0091-2700
eISSN :
1552-4604
Publisher :
Wiley-Blackwell, Hoboken, United States - New Jersey
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) 2015, The American College of Clinical Pharmacology.
Available on ORBi :
since 13 February 2015

Statistics


Number of views
42 (3 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
16
Scopus citations®
without self-citations
15
OpenCitations
 
20

Bibliography


Similar publications



Contact ORBi